Arvinas IncNASDAQ:ARVN
- LAST PRICE33.1400
- TODAY'S CHANGE (%)0.9000 (2.7916%)
- Bid / Lots31.8800/ 4
- Ask / Lots34.0000/ 1
- Open / Previous Close32.5700 / 32.2400
- Day Range
- 52 Week Range
- Volume1,002,064
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARVN |
|---|---|---|
| 09:32 ET | 3798 | 32.525 |
| 09:34 ET | 1137 | 32.72 |
| 09:36 ET | 1900 | 32.855 |
| 09:38 ET | 12284 | 32.855 |
| 09:39 ET | 2236 | 33.1898 |
| 09:41 ET | 3500 | 33.23 |
| 09:43 ET | 811 | 33.31 |
| 09:45 ET | 1382 | 33.375 |
| 09:48 ET | 400 | 33.48 |
| 09:50 ET | 451 | 33.57 |
| 09:52 ET | 1506 | 33.545 |
| 09:54 ET | 1916 | 33.39 |
| 09:56 ET | 1200 | 33.44 |
| 09:57 ET | 1460 | 33.3 |
| 09:59 ET | 100 | 33.4196 |
| 10:01 ET | 108 | 33.21 |
| 10:03 ET | 600 | 33.24 |
| 10:08 ET | 100 | 33.115 |
| 10:10 ET | 708 | 33.05 |
| 10:12 ET | 700 | 32.97 |
| 10:14 ET | 989 | 32.975 |
| 10:15 ET | 1500 | 33.105 |
| 10:17 ET | 503 | 33.2 |
| 10:19 ET | 700 | 33.195 |
| 10:21 ET | 600 | 33.22 |
| 10:24 ET | 300 | 33.29 |
| 10:26 ET | 400 | 33.385 |
| 10:28 ET | 1699 | 33.305 |
| 10:30 ET | 1200 | 33.205 |
| 10:32 ET | 988 | 33.125 |
| 10:33 ET | 1844 | 33.03 |
| 10:35 ET | 400 | 33.025 |
| 10:37 ET | 1000 | 32.94 |
| 10:39 ET | 1730 | 33.04 |
| 10:42 ET | 500 | 33.005 |
| 10:44 ET | 1900 | 33 |
| 10:46 ET | 2888 | 32.98 |
| 10:48 ET | 10406 | 32.85 |
| 10:50 ET | 4544 | 32.945 |
| 10:51 ET | 100 | 32.945 |
| 10:53 ET | 285 | 32.99 |
| 10:55 ET | 2900 | 32.98 |
| 10:57 ET | 609 | 33.035 |
| 11:00 ET | 2009 | 33 |
| 11:02 ET | 200 | 33.01 |
| 11:04 ET | 6000 | 32.95 |
| 11:06 ET | 2997 | 32.865 |
| 11:08 ET | 3914 | 32.94 |
| 11:09 ET | 700 | 33.115 |
| 11:11 ET | 100 | 33.08 |
| 11:13 ET | 100 | 33.09 |
| 11:15 ET | 2700 | 32.9725 |
| 11:20 ET | 1742 | 32.985 |
| 11:22 ET | 1542 | 32.99 |
| 11:24 ET | 9870 | 32.97 |
| 11:26 ET | 2600 | 33.04 |
| 11:29 ET | 300 | 33.06 |
| 11:31 ET | 1198 | 33.03 |
| 11:33 ET | 2000 | 32.985 |
| 11:36 ET | 2341 | 32.96 |
| 11:38 ET | 4601 | 33 |
| 11:40 ET | 2400 | 32.905 |
| 11:42 ET | 800 | 32.955 |
| 11:44 ET | 200 | 32.95 |
| 11:45 ET | 908 | 32.95 |
| 11:47 ET | 1000 | 32.985 |
| 11:49 ET | 900 | 33.09 |
| 11:56 ET | 200 | 33.09 |
| 11:58 ET | 800 | 33 |
| 12:00 ET | 1605 | 33 |
| 12:02 ET | 4488 | 32.945 |
| 12:03 ET | 4062 | 32.935 |
| 12:05 ET | 3100 | 32.965 |
| 12:07 ET | 721 | 32.95 |
| 12:09 ET | 600 | 32.955 |
| 12:12 ET | 300 | 32.945 |
| 12:14 ET | 5445 | 32.93 |
| 12:16 ET | 1000 | 32.935 |
| 12:18 ET | 8348 | 32.99 |
| 12:20 ET | 410 | 33.02 |
| 12:21 ET | 356 | 33.01 |
| 12:23 ET | 11200 | 32.95 |
| 12:25 ET | 2853 | 32.99 |
| 12:27 ET | 3141 | 32.985 |
| 12:30 ET | 800 | 32.965 |
| 12:32 ET | 5292 | 32.95 |
| 12:34 ET | 1100 | 32.925 |
| 12:36 ET | 1226 | 32.905 |
| 12:38 ET | 8435 | 32.9 |
| 12:39 ET | 400 | 32.945 |
| 12:41 ET | 200 | 32.95 |
| 12:43 ET | 6404 | 32.945 |
| 12:45 ET | 4290 | 32.97 |
| 12:48 ET | 8847 | 32.765 |
| 12:50 ET | 2347 | 32.675 |
| 12:52 ET | 3091 | 32.77 |
| 12:54 ET | 2118 | 32.71 |
| 12:56 ET | 1100 | 32.69 |
| 12:57 ET | 500 | 32.635 |
| 12:59 ET | 2592 | 32.63 |
| 01:01 ET | 1000 | 32.71 |
| 01:03 ET | 1075 | 32.75 |
| 01:06 ET | 1000 | 32.72 |
| 01:08 ET | 899 | 32.74 |
| 01:10 ET | 5422 | 32.735 |
| 01:12 ET | 1400 | 32.78 |
| 01:14 ET | 600 | 32.77 |
| 01:15 ET | 1014 | 32.79 |
| 01:17 ET | 3000 | 32.785 |
| 01:19 ET | 100 | 32.785 |
| 01:21 ET | 400 | 32.775 |
| 01:24 ET | 2108 | 32.88 |
| 01:26 ET | 1815 | 32.875 |
| 01:28 ET | 1300 | 32.935 |
| 01:30 ET | 3541 | 32.8675 |
| 01:32 ET | 1604 | 32.88 |
| 01:33 ET | 1200 | 32.87 |
| 01:35 ET | 200 | 32.87 |
| 01:37 ET | 1100 | 32.78 |
| 01:39 ET | 1587 | 32.78 |
| 01:42 ET | 6200 | 32.8925 |
| 01:44 ET | 1600 | 32.935 |
| 01:46 ET | 4200 | 32.92 |
| 01:48 ET | 300 | 32.93 |
| 01:50 ET | 300 | 32.93 |
| 01:51 ET | 1551 | 33.02 |
| 01:53 ET | 1620 | 33.02 |
| 01:55 ET | 600 | 32.98 |
| 01:57 ET | 935 | 32.935 |
| 02:00 ET | 590 | 32.9144 |
| 02:02 ET | 856 | 32.92 |
| 02:04 ET | 3166 | 32.935 |
| 02:06 ET | 2500 | 32.935 |
| 02:08 ET | 3808 | 32.905 |
| 02:09 ET | 2300 | 32.895 |
| 02:11 ET | 4186 | 32.99 |
| 02:13 ET | 1996 | 33.035 |
| 02:15 ET | 300 | 32.98 |
| 02:18 ET | 500 | 33.02 |
| 02:20 ET | 1236 | 33 |
| 02:22 ET | 2200 | 32.98 |
| 02:24 ET | 1400 | 33 |
| 02:26 ET | 200 | 33.01 |
| 02:27 ET | 1400 | 32.99 |
| 02:29 ET | 2000 | 32.99 |
| 02:31 ET | 4100 | 32.945 |
| 02:33 ET | 500 | 32.945 |
| 02:36 ET | 3900 | 32.99 |
| 02:38 ET | 2183 | 32.98 |
| 02:40 ET | 8400 | 32.935 |
| 02:42 ET | 3700 | 32.955 |
| 02:44 ET | 2608 | 32.995 |
| 02:45 ET | 700 | 32.98 |
| 02:47 ET | 1694 | 33 |
| 02:49 ET | 2188 | 32.95 |
| 02:51 ET | 2445 | 32.935 |
| 02:54 ET | 4048 | 32.92 |
| 02:56 ET | 1521 | 32.92 |
| 02:58 ET | 2000 | 32.965 |
| 03:00 ET | 3695 | 32.95 |
| 03:02 ET | 3073 | 32.95 |
| 03:03 ET | 2255 | 32.95 |
| 03:05 ET | 8798 | 32.965 |
| 03:07 ET | 3948 | 32.94 |
| 03:09 ET | 1221 | 33.05 |
| 03:12 ET | 300 | 33.04 |
| 03:14 ET | 3400 | 33.105 |
| 03:16 ET | 3948 | 33.15 |
| 03:18 ET | 481 | 33.174 |
| 03:20 ET | 3544 | 33.1925 |
| 03:21 ET | 2901 | 33.17 |
| 03:23 ET | 500 | 33.195 |
| 03:25 ET | 2715 | 33.2694 |
| 03:27 ET | 2800 | 33.38 |
| 03:30 ET | 2200 | 33.26 |
| 03:32 ET | 3242 | 33.235 |
| 03:34 ET | 9874 | 33.12 |
| 03:36 ET | 2500 | 33.235 |
| 03:38 ET | 2940 | 33.24 |
| 03:39 ET | 700 | 33.27 |
| 03:41 ET | 9613 | 33.245 |
| 03:43 ET | 4459 | 33.195 |
| 03:45 ET | 3962 | 33.25 |
| 03:48 ET | 5500 | 33.22 |
| 03:50 ET | 6801 | 33.24 |
| 03:52 ET | 9072 | 33.21 |
| 03:54 ET | 5209 | 33.1828 |
| 03:56 ET | 13250 | 33.2 |
| 03:57 ET | 5902 | 33.155 |
| 03:59 ET | 258949 | 33.14 |
May 23, 2024
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress, from 5:00PM ET on Thursday May 23, 2024 by Dow Jones
5:00PM ET on Thursday May 23, 2024 by Dow Jones
May 17, 2024
DJ Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co., from 10:48AM ET on Friday May 17, 2024 by Dow Jones
10:48AM ET on Friday May 17, 2024 by Dow Jones
May 16, 2024
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE(R)), from 6:00AM ET on Thursday May 16, 2024 by Dow Jones
6:00AM ET on Thursday May 16, 2024 by Dow Jones
May 9, 2024
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, from 4:42PM ET on Thursday May 09, 2024 by Dow Jones
4:42PM ET on Thursday May 09, 2024 by Dow JonesDJ Arvinas Is Maintained at Overweight by Wells Fargo, from 12:07PM ET on Thursday May 09, 2024 by Dow Jones
12:07PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arvinas Inc | 2.3B | -5.5x | --- |
Rhythm Pharmaceuticals Inc | 2.2B | -7.7x | --- |
Kymera Therapeutics Inc | 2.0B | -12.8x | --- |
Intellia Therapeutics Inc | 2.1B | -4.0x | --- |
Recursion Pharmaceuticals Inc | 2.0B | -5.1x | --- |
Celldex Therapeutics Inc | 2.2B | -11.7x | --- |
Company Information
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Contact Information
- Headquarters
- 5 Science ParkNEW HAVEN, CT, United States 06511-1966
- Phone
- 203-535-1456
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- John Houston
- Interim Chief Financial Officer, Chief Business Officer, Treasurer
- Randy Teel
- Chief Scientific Officer
- Ian Taylor
- General Counsel
- Jared Freedberg
- Chief Medical Officer
- Noah Berkowitz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
|---|---|
Revenue (TTM) | $71.3M |
Shares Outstanding | 68.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-6.05 |
Book Value | $9.71 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | 31.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -556.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
